XORTX Therapeutics Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
other
SEC Category
Non-accelerated filerEmerging growth company
State of Incorporation
British Columbia, Canada
Business Address
SUITE 2400 - 745 THURLOW STREET, VANCOUVER, A1, V6E 0C5
Mailing Address
SUITE 2400 - 745 THURLOW STREET, VANCOUVER, A1, V6E 0C5
Phone
403-607-2621
Fiscal Year End
1231
EIN
000000000
Financial Overview
FY2021
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 6-K Foreign company current report | April 1, 2026 | View on SEC |
| 6-K Foreign company current report | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 27, 2026 | View on SEC |
| 6-K Foreign company current report | March 26, 2026 | View on SEC |
| 6-K Foreign company current report | March 24, 2026 | View on SEC |
| 20-F Foreign company annual report | March 20, 2026 | View on SEC |
| 6-K Foreign company current report | March 19, 2026 | View on SEC |
| 6-K Foreign company current report | March 13, 2026 | View on SEC |
| 6-K Foreign company current report | March 5, 2026 | View on SEC |
Annual Reports
20-F
March 20, 2026
- Successfully secured significant funding in 2025 through various offerings, including common shares, pre-funded units, and warrants.
- Maintained key license agreements with the University of Florida Research Foundation, securing exclusive rights to its core technology and drug programs.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.